Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH and Fibrotic Diseases

 Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH and Fibrotic Diseases

Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH and Fibrotic Diseases

Shots:

  • Pliant to receive $80M including upfront & equity investment and eligible to receive development, regulatory and commercial milestones with royalties on sales. Novartis to get exclusive WW license for Pliant’s PLN-1474 and up to three additional candidates
  • Novartis will be responsible for all future development, manufacturing and commercial activities, a post-P-I study of PLN-1474, prior to which Pliant will be responsible for all activities
  • PLN-1474 is a pre-clinical candidate that selectively inhibit integrin αVβ1, currently being developed for the treatment of liver fibrosis associated with NASH with its expected IND submission to the US FDA by the year-end 2019

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Straitstimes

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post